[go: up one dir, main page]

BR9914451A - Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento - Google Patents

Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento

Info

Publication number
BR9914451A
BR9914451A BR9914451-4A BR9914451A BR9914451A BR 9914451 A BR9914451 A BR 9914451A BR 9914451 A BR9914451 A BR 9914451A BR 9914451 A BR9914451 A BR 9914451A
Authority
BR
Brazil
Prior art keywords
compound
composition
preparation
treatment methods
pharmaceutical composition
Prior art date
Application number
BR9914451-4A
Other languages
English (en)
Inventor
Kouji Hattori
Akira Tanaka
Yutaka Kono
Shoko Nakazato
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP6176A external-priority patent/AUPP617698A0/en
Priority claimed from AUPP9822A external-priority patent/AUPP982299A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9914451A publication Critical patent/BR9914451A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO DE OXAZOL, PROCESSO PARA SUA PREPARAçãO, COMPOSIçãO FARMACêUTICA COMPREENDENDO DITO COMPOSTO, USO DA COMPOSIçãO E MéTODOS DE TRATAMENTO". Compostos de oxazol da fórmula: onde: R¹ é arila que pode ser substituído com halogênio (s), R² é arila que pode ser substituído com halogênio (s), X é ligação simples, C ou SO~ 2~, R³ e R^ 4^ são independentemente hidrogênio ou substituinte adequado, (onde X é C, nem R³ e nem R^ 4^ é hidrogênio) R³ e R^ 4^ podem ser ligados para formar -<sym>, -<sym> é grupo heterocíclico contendo N que pode ser substituído com um ou mais substituinte (s) adequado (s), R^ 5^ é hidrogênio, etc., A^ 1^ é alquileno inferior ou ligação simples, <sym> é cicloalcano (C~ 3~-C~ 9~) ou ciclo alqueno (C~ 5~-C~ 9~), ou um profármaco do mesmo, ou um sal farmaceuticamente aceitável do mesmo, que são úteis como medicamento.
BR9914451-4A 1998-09-25 1999-09-24 Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento BR9914451A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP6176A AUPP617698A0 (en) 1998-09-25 1998-09-25 Oxazole compounds
AUPP9822A AUPP982299A0 (en) 1999-04-19 1999-04-19 Oxazole compounds
PCT/JP1999/005212 WO2000018744A1 (en) 1998-09-25 1999-09-24 Oxazole compounds as prostaglandin e2 agonists or antagonists

Publications (1)

Publication Number Publication Date
BR9914451A true BR9914451A (pt) 2001-05-22

Family

ID=25645884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914451-4A BR9914451A (pt) 1998-09-25 1999-09-24 Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento

Country Status (10)

Country Link
US (1) US6437146B1 (pt)
EP (1) EP1115712A1 (pt)
JP (1) JP2002525361A (pt)
KR (1) KR20010075136A (pt)
CN (1) CN1328550A (pt)
BR (1) BR9914451A (pt)
CA (1) CA2345474A1 (pt)
HK (1) HK1041486A1 (pt)
HU (1) HUP0103511A3 (pt)
WO (1) WO2000018744A1 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE404553T1 (de) * 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) * 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
MXPA04009243A (es) * 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
US7547715B2 (en) 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
EP1697337A2 (en) * 2003-12-22 2006-09-06 Astellas Pharma Inc. Ornithine derivatives as prostaglandin-e2-agonists or antagonists
EP1742662A2 (en) * 2004-05-03 2007-01-17 Astellas Pharma Inc. Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
EP1807078A1 (en) 2004-10-07 2007-07-18 Vitae Pharmaceuticals, Inc. Diaminoalkane aspartic protease inhibitors
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
EP1846354B1 (en) 2005-01-14 2010-04-28 Allergan, Inc. Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
RU2412933C2 (ru) * 2005-03-10 2011-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
ATE515263T1 (de) * 2005-05-06 2011-07-15 Allergan Inc Substituierte beta-lactame und deren verwendung in der medizin
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614068D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614062D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
CA2660396A1 (en) * 2006-08-09 2008-02-21 Allergan, Inc. Therapeutic amides and related compounds
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
WO2008073752A2 (en) 2006-12-11 2008-06-19 Allergan, Inc. Cyclobutyl derivatives for the treatment of glaucoma
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
WO2008082217A1 (en) * 2006-12-28 2008-07-10 Lg Electronics Inc. Ice making system and method for ice making of refrigerator
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CA2639412A1 (en) 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2297084A1 (en) * 2008-04-24 2011-03-23 Allergan, Inc. Therapeutic compounds
AU2009239369B2 (en) * 2008-04-24 2014-03-06 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin EP2 agonists
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
CA2722403C (en) * 2008-04-24 2017-03-07 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
EP2291367A1 (en) 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
ATE550328T1 (de) * 2008-04-24 2012-04-15 Allergan Inc Thiophenderivate, die sich als den augeninnendruck senkende mittel eignen
AU2009239372B2 (en) * 2008-04-24 2013-09-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US7713967B2 (en) 2008-05-09 2010-05-11 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
AU2009244513B2 (en) * 2008-05-09 2014-04-10 Allergan, Inc. Therapeutic cyclopentane derivatives
EP2285796A1 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
JP2011519939A (ja) * 2008-05-09 2011-07-14 アラーガン インコーポレイテッド 治療用化合物
BRPI0912344A2 (pt) * 2008-05-09 2015-10-13 Allergan Inc derivados terapêuticos de n-aril ou n-heteroaril pirazolidina e pirazolidinona
WO2009137411A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US8592413B2 (en) * 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
CA2724605A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin prodrugs as hypotensive agents
EP2149554A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
US7985765B2 (en) * 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
SG176628A1 (en) 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
BR112012022947B1 (pt) * 2010-03-31 2021-06-15 Toray Industries, Inc Agente terapêutico ou agente profilático para a fibromialgia
RU2559318C2 (ru) * 2010-03-31 2015-08-10 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для лечения нарушения накопления мочи
CA2800936A1 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
GB201321601D0 (en) * 2013-12-06 2014-01-22 Canbex Therapeutics Ltd Modulator
US9637477B2 (en) 2014-05-20 2017-05-02 Allergan, Inc. Therapeutic substituted pyrroles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901908A (en) 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362897A (en) * 1993-04-30 1994-11-08 Toagosei Chemical Industry Co., Ltd. Process for producing trialkoxysilanes
DK0736018T3 (da) 1993-12-20 2000-09-18 Fujisawa Pharmaceutical Co 4,5-Diaryloxazolderivater
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists

Also Published As

Publication number Publication date
CA2345474A1 (en) 2000-04-06
CN1328550A (zh) 2001-12-26
JP2002525361A (ja) 2002-08-13
HK1041486A1 (zh) 2002-07-12
HUP0103511A2 (hu) 2002-01-28
WO2000018744A1 (en) 2000-04-06
KR20010075136A (ko) 2001-08-09
HUP0103511A3 (en) 2002-07-29
US6437146B1 (en) 2002-08-20
EP1115712A1 (en) 2001-07-18

Similar Documents

Publication Publication Date Title
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
DE69100079D1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
BR0005703A (pt) Compostos de sulfamoil-heteroarilpirazole com agentes anti-inflamatórios/analgésicos
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
RU94028888A (ru) Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция
NO940523D0 (no) Nye pyrazin-derivater
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
ATE305473T1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE59632T1 (de) Dihydrodibenzocycloheptylidenethylamin-derivate
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
DE3869075D1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
BR0010225A (pt) Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso
BR0013306A (pt) Processos úteis na sìntese de compostos antipicornavirais
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]